AlgoTherapeutix appoints Jean-François Labbé, Hugues Le Bret and Fabrice Aurousseau to Board of Directors

Paris, May 1st 2019

In order to strengthen its strategic and operational ability, AlgoTherapeutix appointed a new Board of Directors consisting of Jean-François Labbé (Chairman), Hugues le Bret and Fabrice Aurousseau as well as Stéphane Thiroloix, Founder and CEO of AlgoTherapeutix.

Jean-François Labbé

Jean-François Labbé (MBA), founded SpePharm Holding BV and was its CEO from 2006 to 2012. He was previously CEO of OTL Pharma SA from 2001 to 2004, COO of ProStrakan UK from 2004 to 2005, and Pdt of Parke-Davis France/ Warner-Lambert (Pfizer Group) from 1999 to 2001. Jean-François began his career at Hoechst Roussel in 1974, held GM positions in Europe, South Africa and the US. In 1995, he was appointed President, Europe Middle East Africa and member of the ExCom of Hoechst Marion Roussel until its merger with Aventis in 1999. He is a Board member at NicoxSA and Deinove, and served on the Board of Transgene.

Hugues Le Bret.

Hugues Le Bret is the Founder & Pdt of the Supervisory Board of Compte-Nickel since 2012. He became Adviser to the CEO of BNP Paribas in 2017 when the latter acquired Compte-Nickel. From 1999 to 2009 he was the Pdt & CEO of Boursorama, after being Dir of communication & ExCom member at Société Générale. Hugues started as an economy journalist in 1987, then worked at  Publicis for 3 years. He founded ABW in 1993, a financial communication company sold to Havas in 1996, and was then CEO of financial communication activities at Havas until 1999.

Board of Directors
Fabrice Aurousseau

Fabrice Aurousseau (IEP / Sc.Po, Master in Public Law), is the Co-Founder of the M&A Advisory firm Eponyme Partners, and the CEO & Co-founder of the R&D consulting firm PPRS Research. He served previously in activities of Corporate Finance at Compagnie Financière E. de Rothschild and BNP Paribas. 

Stéphane Thiroloix

Stéphane Thiroloix (HEC) is the Founder, President & CEO of AlgoTherapeutix. Stephane is the Chairman of the Board at Jellagen Marine Biotechnologies, and strategic advisor to Hoalen and Ythera. Prior to founding AlgoTherapeutix, Stephane served as CEO of Mayoly-Spindler (2014-2018), EVP Europe at Smith&Nephew (2012-2014), EVP Corporate Dvt at Ipsen (2007-2012), VP Europe & GM France at Bristol-Myers Squibb (2002-2007), VP Europe Business Dvt at GSK (1998-2002). Stephane started his career at Roussel Uclaf (HMR / Sanofi) and occupied central and affiliate leadership positions between 1987 and 1998.

AlgoTherapeutix is a French biotech start-up, hosted by the Paris Biotech Santé incubator developing ATX01, a treatment for Chemotherapy-Induced Peripheral Neuropathy.

AlgoTherapeutix SAS

49 rue des Nouvelles – 92150 Suresnes

Contact- contact@algotx.com

Communication : Geneviève Cliquet Consultant – T: +33(0) 607 500 567

contact@cliquet-consultant.com

1 commentaire
  • Un commentateur WordPress

    Bonjour, ceci est un commentaire.
    Pour débuter avec la modération, la modification et la suppression de commentaires, veuillez visiter l’écran des Commentaires dans le Tableau de bord.
    Les avatars des personnes qui commentent arrivent depuis Gravatar.

Les commentaires sont fermés.